News

Milan, 25 September 2024
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic

Milan, 12 September 2024
Genespire appoints Karen Aiach-Pignet as Chief Executive Officer

Milan, 9 May 2024
Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting

Milan, 7 July 2022
Genespire appoints Dr. Sabah Sallah as Chief Medical Officer

Milan, 13 July 2021
Genespire appoints Phillippe Mauberna as Chief Financial Officer

Milan, May 5, 2021
Genespire Strengthens Management Team with Two Key Appointments

Milan, July 30, 2020
Genespire appoints Jörn Aldag as Chairman of the Board of Directors

Milan, June 30, 2020
Genespire and the San Raffaele Telethon Institute for Gene Therapy announce publication in Nature Biotechnology on enhanced gene editing technique in hematopoietic stem cells

Milan, May 13, 2020
Genespire and SR-Tiget announce strategic alliance for the development of transformative gene therapies for genetic diseases and disclose collaboration focus

Milan, April 29, 2020
Genespire Secures €16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies